Skip to main content
. Author manuscript; available in PMC: 2021 Sep 2.
Published in final edited form as: ACS Appl Mater Interfaces. 2020 Aug 24;12(35):38950–38961. doi: 10.1021/acsami.0c10276

Figure 5.

Figure 5.

Resiquimod dose vaccine study with medium sized MC. Mice were immunized on Day 0 (prime) and Day 21 (boost). Blood draws were done on Days −7 and 28. Total IgG (A), IgG1 (B), and IgG2c (C) endpoint anti-OVA antibody titers from day 28. Titers were log transformed and represented as mean ± standard deviation. ***p < 0.0005, ****p < 0.0001 for comparisons to soluble resiquimod dose counterpart. +p < 0.05, ++p < 0.01, ++++p < 0.0001 for comparisons to OVA only.